These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 9688185

  • 1. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity.
    Lai R, Medeiros LJ, Wilson CS, Sun NC, Koo C, McCourty A, Brynes RK.
    Mod Pathol; 1998 Jul; 11(7):642-7. PubMed ID: 9688185
    [Abstract] [Full Text] [Related]

  • 2. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression.
    Hiyama H, Iavarone A, LaBaer J, Reeves SA.
    Oncogene; 1997 May 29; 14(21):2533-42. PubMed ID: 9191053
    [Abstract] [Full Text] [Related]

  • 3. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
    Pruneri G, Carboni N, Baldini L, Intini D, Colombi M, Bertolini F, Valentini S, Maisonneuve P, Viale G, Neri A.
    Hum Pathol; 2003 Jan 29; 34(1):41-7. PubMed ID: 12605365
    [Abstract] [Full Text] [Related]

  • 4. Down-regulation of cyclin A gene expression upon genotoxic stress correlates with reduced binding of free E2F to the promoter.
    Spitkovsky D, Schulze A, Boye B, Jansen-Dürr P.
    Cell Growth Differ; 1997 Jun 29; 8(6):699-710. PubMed ID: 9186003
    [Abstract] [Full Text] [Related]

  • 5. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E.
    Int J Clin Pract; 2008 Nov 29; 62(11):1736-43. PubMed ID: 19143860
    [Abstract] [Full Text] [Related]

  • 6. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.
    Wilson CS, Butch AW, Lai R, Medeiros LJ, Sawyer JR, Barlogie B, McCourty A, Kelly K, Brynes RK.
    Br J Haematol; 2001 Mar 29; 112(3):776-82. PubMed ID: 11260083
    [Abstract] [Full Text] [Related]

  • 7. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma.
    Izban KF, Alkan S, Singleton TP, Hsi ED.
    Arch Pathol Lab Med; 2000 Oct 29; 124(10):1457-62. PubMed ID: 11035575
    [Abstract] [Full Text] [Related]

  • 8. K-ras modulates the cell cycle via both positive and negative regulatory pathways.
    Fan J, Bertino JR.
    Oncogene; 1997 May 29; 14(21):2595-607. PubMed ID: 9191059
    [Abstract] [Full Text] [Related]

  • 9. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
    Schulze A, Zerfass K, Spitkovsky D, Henglein B, Jansen-Dürr P.
    Oncogene; 1994 Dec 29; 9(12):3475-82. PubMed ID: 7970707
    [Abstract] [Full Text] [Related]

  • 10. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity.
    Johnson DG.
    Oncogene; 1995 Nov 02; 11(9):1685-92. PubMed ID: 7478595
    [Abstract] [Full Text] [Related]

  • 11. Functional interplay between p53 and E2F through co-activator p300.
    Lee CW, Sørensen TS, Shikama N, La Thangue NB.
    Oncogene; 1998 May 28; 16(21):2695-710. PubMed ID: 9652736
    [Abstract] [Full Text] [Related]

  • 12. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
    Takahashi Y, Oda Y, Kawaguchi K, Tamiya S, Yamamoto H, Suita S, Tsuneyoshi M.
    Mod Pathol; 2004 Jun 28; 17(6):660-9. PubMed ID: 15098008
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M, Berberich SJ.
    Oncogene; 2002 Jun 27; 21(28):4414-21. PubMed ID: 12080472
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Roles of E2F1 in mesangial cell proliferation in vitro.
    Inoshita S, Terada Y, Nakashima O, Kuwahara M, Sasaki S, Marumo F.
    Kidney Int; 1999 Dec 27; 56(6):2085-95. PubMed ID: 10594784
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.
    Møller MB, Kania PW, Ino Y, Gerdes AM, Nielsen O, Louis DN, Skjødt K, Pedersen NT.
    Leukemia; 2000 May 27; 14(5):898-904. PubMed ID: 10803523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.